S-1/A: Dror Ortho-Design Files Amendment No. 2 to Form S-1, Aiming to Resell Over 2.3 Billion Shares

Dror Ortho-Design, Inc. files an amendment to its Form S-1 registration statement to register the resale of over 2.3 billion shares of common stock by selling securityholders.

Summary

• Dror Ortho-Design, Inc. has filed Amendment No. 2 to its Form S-1 registration statement with the SEC.
• The filing pertains to the offer and sale of 2,304,316,461 shares of common stock by selling securityholders.
• These shares include 293,145,818 shares of Common Stock, 1,046,336,224 shares underlying Series A Convertible Preferred Stock, 474,999,993 shares underlying Private Placement Warrants, and 489,834,426 shares underlying Share Exchange Warrants.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders, but may receive proceeds from the exercise of warrants.
• The company intends to use proceeds from warrant exercises, if any, for general corporate purposes.
• The selling securityholders may resell shares at a fixed price of $0.011 per share until the common stock is listed on a public trading market, and thereafter at prevailing market prices.
• The company's common stock is currently quoted on the OTC Pink Market under the symbol DROR, with the last reported sales price on June 4, 2024, at $0.0035 per share.

Sentiment

Score: 5

Explanation: The document is primarily a registration statement, which is neutral in tone. While it highlights the company's plans and offerings, it also acknowledges risks and uncertainties.

Positives

• The company may receive proceeds from the exercise of warrants, providing potential capital for general corporate purposes.

Negatives

• The company will not receive any proceeds from the resale of shares by the selling securityholders.
• The company's common stock is currently trading at a very low price ($0.0035 per share) on the OTC Pink Market.

Risks

• Investment in the company's common stock involves risk, as detailed in the Risk Factors section of the prospectus.
• The company is in the development stage and is not generating revenues.
• The company faces competition from established aligner companies.
• The company's common stock is not listed on any stock exchange and has a limited market.

Future Outlook

The company intends to use proceeds from warrant exercises, if any, for general corporate purposes and is preparing to apply for 510(k) clearance for its Platform.

Industry Context

The company aims to disrupt the aligner market by offering a revolutionary alternative to traditional aligner solutions.

Comparison to Industry Standards

• The document mentions Align Technologies, SmileDirectClub, Dentsply Sirona, 3M Clarity Aligners, and Straumann Group as competitors in the clear aligner market.
• The company's solution differs from traditional aligners by using only one smart aligner with pulsating air, while existing solutions generally require a series of aligners worn throughout the day.

Stakeholder Impact

• Shareholders may experience dilution from the potential exercise of warrants and conversion of preferred stock.
• The company's future success depends on market acceptance of its Platform and its ability to compete with established companies.

Next Steps

• The selling securityholders may offer or sell the shares of common stock from time to time through public or private transactions.
• The company intends to apply to have its common stock listed for trading on The Nasdaq Stock Market.

Key Dates

Keywords

common stock, Dror Ortho-Design, resale, selling securityholders, Series A Preferred Stock, warrants, private placement, share exchange, OTC Pink Market, registration statement